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Activation of the ERK1/2 pathway is involved in malignant transformation both in vitro and in vivo. Little is known about the role of
activated ERK1/2 in non-small cell lung cancer (NSCLC). The purpose of this study was to characterise the extent of the activation of
ERK1/2 by immunohistochemistry in patients with NSCLC, and to determine the relationship of ERK1/2 activation with
clinicopathological variables. Specimens from 111 patients with NSCLC (stages I– IV) were stained for P-ERK. Staining for epidermal
growth factor receptor (EGFR) and Ki-67 was also performed. In all, 34% of the tumour specimens showed activation for ERK1/2,
while normal lung epithelial tissue was consistently negative. There was a strong statistical correlation between nuclear and
cytoplasmic P-ERK staining and advanced stages (Po0.05 and Po0.001, respectively), metastatic hilar or mediastinal lymph nodes
(Po0.01, Po0.001), and higher T stages (Po0.01, Po0.001). We did not find correlation of nuclear or cytoplasmic P-ERK staining
with either EGFR expression or Ki-67 expression. Total ERK1/2 expression was evaluated with a specific ERK1/2 antibody and
showed that P-ERK staining was not due to ERK overexpression but rather to hyperactivation of ERK1/2. Patients with a positive P-
ERK cytoplasmic staining had a significant lower survival (Po0.05). However, multivariate analysis did not show significant survival
difference. Our study indicates that nuclear and cytoplasmic ERK1/2 activation positively correlates with stage, T and lymph node
metastases, and thus, is associated with advanced and aggressive NSCLC tumours.
British Journal of Cancer (2004) 90, 1047–1052. doi:10.1038/sj.bjc.6601644 www.bjcancer.com
& 2004 Cancer Research UK
Keywords: NSCLC; MAPK; EGFR; Ki-67























































In the United States and Europe, lung cancer is the leading cause of
cancer death. Non-small cell lung cancer (NSCLC) is the most
common type, accounting for 75 –80% of all lung cancers (Dy and
Adjei, 2002a). In spite of important advances in surgery, radiation,
chemotherapy, and the efforts involved in early detection and
prevention, the survival of patients with NSCLC has not changed
significantly over the past 20 years (Devesa et al, 1995). This is due
to the fact that patients with early stage disease can be effectively
treated with surgery, but most patients present at diagnosis with
advanced stage, which is essentially incurable, since systemic
chemotherapy has poor long-term results in these patients. Even
after surgery, 50% of operated patients will develop metastatic
disease (Dy and Adjei, 2002a). All these facts emphasise the need
for new early detection tools and for more effective therapies. Our
knowledge of the molecular events associated with the biology of
NSCLC has substantially increased over the past decade, and
extensive molecular and cytogenetic alterations have been
characterised in these tumours (Fong et al, 1999). Many molecular
mechanisms associated with the pathogenesis of lung cancer offer
the exciting possibility of becoming new targets for lung cancer
therapy (Dy and Adjei, 2002a, b). A better understanding of the
molecular mechanisms involved in lung carcinogenesis and in the
progression of this disease is urgently needed to design effective
treatments.
One of the signalling pathways that has been extensively studied
in vitro is the RAS–RAF–MEK–ERK pathway. Most of the studies
carried out to characterise this pathway have been conducted in
fibroblasts, although more recently there is also an increasing
number of studies in epithelial cell lines (Cobb, 1999). The
extracellular signal regulated kinase (ERK1/2) also called the
mitogen-activated protein kinase (MAPK), is activated by dual
phosphorylation on both Thr202 and Tyr204 residues. This
activation is mediated by activated MEK1, which in turn is
phosphorylated by RAF-1, and RAF-1 is activated by RAS (for
reviews see Cobb, 1999; Widmann et al, 1999; Chang and Karin,
2001). The only known substrates of MEK1 are ERK1 and ERK2,
which makes MEK1 an important point to control ERK signalling,
and a potential therapeutic target. Activated ERK1 and ERK2 can
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phosphorylate a variety of nuclear substrates such as the
transcription factors Elk-1, Ets1 and Sap1a, and also cytosolic
targets such as phospholipase A2, and S6 Kinase p90rsk among
others (Widmann et al, 1999). Growth factors such as EGF, HGF
and PDGF, as well as a variety of other stimuli activate ERK1/2,
and activation of this kinase has been frequently associated with
proliferation or differentiation depending on several factors such
as cellular context and the length of the activation (Widmann et al,
1999). It is also known that several oncogenes can constitutively
activate ERK, and that this uncontrolled activation of ERK can lead
to malignant transformation both in vitro and in vivo (Webb et al,
1998). Furthermore, activated ERK1/2 and/or increased levels of
ERK1/2 have been reported in a variety of human tumour cell lines
(Hoshino et al, 1999) and epithelial cancer tissues such as breast
(Sivaraman et al, 1997; Adeyinka et al, 2002), kidney (Oka et al,
1995), colon (Sebolt-Leopold et al, 1999) and head and neck
cancers (Albanell et al, 2001). More recently, Blackhall et al (2003)
have shown P-ERK activation in small cell lung cancer (SCLC) of a
high percentage of patients studied. Although there is some
evidence of the presence of activated ERK1/2 in NSCLC primary
cancer cells derived from tumours as compared to normal lung
cells (Hoshino et al, 1999), the extent of this activation and its
meaning and role in patients with NSCLC remain to be defined.
Therefore, we analysed the expression of phosphorylated (acti-
vated) ERK1/2 by immunohistochemistry with a phosphospecific
antibody in a nonselected patient population with histologically
proven NSCLC, and made correlations of the expression of this
kinase with different clinical parameters and with survival, in an
attempt to understand the role of activated ERK1/2 in these
patients.
MATERIAL AND METHODS
Tissue specimens and patient characteristics
All patients were treated at the University Hospital of the University
of Navarra (Clı´nica Universitaria de Navarra, Pamplona, Spain)
from December 1994 to June 2003. Paraffin-embedded tissue
specimens from 111 patients were obtained according to institu-
tional review board-approved protocols. These tissue specimens
were obtained either from biopsies of the primary tumours
corresponding to patients with advanced nonoperable NSCLC or
from surgical specimens in those patients who were operated. In
both cases, biopsy specimens were obtained prior to any chemo- or
radiation therapy treatment. All the samples were fixed in 10%
buffered formalin. Sections (5mm) from the paraffin tissue blocks
were processed for immunohistochemical analysis. One section was
stained with haematoxylin and eosin (H&E) and reviewed by at least
two pathologists to confirm the presence of NSCLC in the specimen,
and also for appropriate histopathological characterisation.
All patients had an ECOG performance status of 0 or 1, adequate
baseline organ function (defined as a leucocyte count 43 109 l1
(absolute granulocyte count 41.5 109 l1), platelet count
475 109 l1, normal liver function tests and serum creatinine
level o1.4 mg dl1) and no other severe co-morbid conditions. A
written signed informed consent was obtained from all patients
before treatment.
Patient stage was determined according to the TNM staging
system. Surgery was performed as the initial treatment for
medically operable stages I, II and IIIA (non-N2 tumours).
Lobectomy and ipsilateral mediastinal lymph node sampling was
the treatment of choice. Postoperative radiotherapy was added
depending on the pathologic findings. Specifically, radiation
therapy was recommended with pathologically confirmed meta-
static hilar or mediastinal lymph nodes. Postoperative radio-
therapy consisted of 45 grays (Gy) using conventional fields and
fractionation schedules.
Patients with locally advanced NSCLC were initially treated with
chemotherapy. Intravenous infusions of paclitaxel 135 mg m2
over 3 h and cisplatin 120 mg m2 over 6 h were delivered on day 1.
Either vinorelbine 30 mg m2 or gemcitabine 800 mg m2 over
30 min was administered on days 1 and 8. Cycles were repeated
every 4 weeks. Four cycles were delivered to responding patients
before administering radical radiotherapy with concurrent che-
motherapy. Patients who did not respond to this treatment were
administered radical hyperfractionated radiotherapy (69.6 Gy)
soon after progression to chemotherapy was detected. Stage IV
patients were treated with the chemotherapy schedule previously
described for stage III patients. Median follow-up time of the
whole group was 30 months (range 1– 87).
Clinicopathological characteristics including age, gender, histol-
ogy, stage and grade of differentiation were evaluated. We also
evaluated the expression of the epidermal growth factor receptor
(EGFR) and the nuclear antigen Ki-67 by immunohistochemistry
in order to assess whether there was any correlation between
activation of ERK1/2 and the expression of EGFR or the
proliferation.
Immunohistochemistry
Samples from 111 patients were studied by immunohistochem-
istry. Rabbit polyclonal antibodies specific against the dual
phosphorylated form of ERK1/2 (Thr202/Tyr204) were used (Cell
Signaling, Beverly, MA, USA) at a dilution of 1 : 100 (determined
after preliminary serial dilution studies). Samples were incubated
overnight at 41C with the primary antibody. Immunocytochemical
reaction was shown using the EnVisions TM intensifying kit
(Dako, Carpinteria, CA, USA). Positive controls were ERK1/2-
activated HTB58 human lung cancer cells fixed in 10% buffered
formalin, which were analysed by immunohistochemistry with the
anti-P-ERK polyclonal antibody. Activation of ERK1/2 was
achieved by culturing the cells in a medium containing 20% fetal
calf serum (FCS) after 16 h of serum deprivation (medium with
0.4% FCS) (data not shown). We also performed Western blot
analyses of the induction of P-ERK after treatment of the cells with
two known activating agents, fetal bovine serum (20%) and TPA
(100 ng ml1) (data not shown). Negative controls consisted of
incubation of serial (positive) lung tumour sections with an
unrelated IgG rabbit polyclonal antibody. The results of the
staining were reviewed independently without knowledge of the
clinicopathological data by three of the co-authors (SVC, CGC and
LMM) who scored the percentage of positive nuclei and/or
cytoplasms within tumours and in the normal matching lung at
high magnification. Average of the scores was registered and no
significant divergence was found in the scoring among the
observers. Serial cuts (3mm) of a subset of the specimens (five
samples that had high percentage of ERK1/2 activation and five
samples that had no activated ERK1/2) were stained using a
specific antibody against total ERK1/2 (Cell Signaling, Beverly,
MA, USA). This experiment was also carried out using a dilution of
1 : 100 as described for the P-ERK antibody. The median
percentage of P-ERK stained cells was 15% and this was chosen
as the cutoff value. A score of 15% or higher was considered
positive. Intensity of the staining was also registered and evaluated
in a semiquantitative way but the intensity of the staining was
fairly similar from specimen to specimen, and its inclusion in the
statistical analysis did not modify the calculations based on
extension alone; therefore, it will not be reported here.
The epidermal growth factor receptor and Ki-67 primary
antibodies were from Novocastra (Newcatle, UK) and were used
at 1 : 20 and 1 : 100 dilutions, respectively. They both were used
according to the manufacturer’s recommendations, including the
use of appropriate positive and negative controls for each
antibody. For the EGFR staining, three of the authors (GT, CGC
and LMM) scored the specimens as positive, when any intensity
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and extension of staining was apparent, or negative when no signs
of staining at all were seen, as described by other authors (Albanell
et al, 2001). A positive score for the Ki-67 staining was considered
when more than 5% of the tumour nuclei were stained as described
before (Xu et al, 2002).
Statistical analysis
All statistical methods used were carried out using the statistical
package SPSS Data Analysis Program version 9.0. The methods
used were the Fisher’s exact test, the w2 test, the Mann–Whitney U-
test, the Kaplan–Meier log rank test and the Cox regression test
for univariate and multivariate survival analysis.
RESULTS
A total of 111 patients with histologically proven NSCLC were
evaluated in this study. The characteristics of these patients are
shown in Table 1. The normal adjacent tissue in 30 of the samples
was also studied. Normal lung tissue was negative for ERK1/2
activation in all the 30 samples studied. Specifically, type I and II
alveolar pneumocytes did not show any staining for P-ERK, and
bronchiolar epithelium was also negative for P-ERK (Figure 1A
and B). Endothelial cells were also negative for P-ERK staining in
the histologically normal areas.
Immunohistochemical staining for P-ERK in the tumours
showed that a variable percentage of cells was stained in each
sample and that the staining could be located in the nucleus or in
the cytoplasm, but most often it was present in both nucleus and
cytoplasm, usually with a predominant staining in the latter. We
recorded and analysed the staining for P-ERK according to its
intracellular location. Examples of positive and negative staining
are shown in Figure 1C –F. For statistical purpose, patients were
arranged in two groups: (a) patients with less than 15% of tumour
cells stained for P-ERK and (b) patients with 15% or more cells
stained. Using this cutoff, specimens were also scored according to
the location of the staining: nuclear staining (with or without
accompanying cytoplasmic staining) or cytoplasmic staining (with
or without accompanying nuclear staining). Although not
reported, the results obtained shifting the cutoff values from 5–
10 to 20– 25% had a similar trend to those shown here using the
cutoff value of 15%. Overall, 65.8% of tumors were negative and
34.2% positive when nuclear and cytoplasmic staining was
considered. Among positive NSCLC, at least half of the tumours
showed ERK1/2 activation preferentially located at the periphery of
the tumour.
We found a strong statistical correlation between a positive
nuclear and cytoplasmic P-ERK staining and advanced stages
(P¼ 0.04, P¼ 0.001), higher T stages (T1–2 vs T3– 4; P¼ 0.005,
P¼ 0.001), and the presence of metastatic lymph nodes (N0 vs N1–
3; P¼ 0.001, P¼ 0.001). However, there was no statistically
significant difference between patients whose tumours had
negative staining vs those patients whose tumours had positive
staining either in the nucleus or in the cytoplasm when comparing
age, sex and histology (squamous cell carcinoma vs adenocarci-
noma) (Table 2). The grade of differentiation was only associated
with cytoplasmic P-ERK staining but not with nuclear staining (1
and 2 vs 3, P¼ 0.046 for cytoplasmic staining and P¼ 0.271 for
nuclear staining).
Staining with a specific total ERK1/2 antibody of a subset of 10
tumour specimens (five negative and five positive for P-ERK
staining) showed the presence of a homogeneous staining for total
Table 1 Characteristics of the patients
No. of patients (n¼ 111) % Total
Age
Median 62
Range 31–87
Gender
Male 93 83.7
Female 18 16.3
Histology
AC 50 46
SC 57 51
Mixt 3 3
T
1 36 32.5
2 48 43.2
3 12 10.8
4 11 9.9
x 3 2.7
Grade
1 9 13
2 28 40.6
3 32 46.4
N
0 73 65.8
1 15 13.5
2 16 14.4
3 7 6.3
Stage
I 62 55.9
II 18 16.2
III 28 25.2
IV 3 2.7
Figure 1 Immunohistochemical staining of normal lung and NSCLC
specimens with a specific antibody against P-ERK: (A) normal alveolar
epithelium, negative staining; (B) normal bronchiolar epithelium, negative
staining; (C) squamous cell carcinoma, negative staining; (D) adenocarci-
noma with nuclear P-ERK staining; (E) squamous cell carcinoma with
cytoplasmic and moderate nuclear staining; (F) adenocarcinoma with
nuclear and extensive cytoplasmic staining.
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ERK1/2 in the 10 specimens independently of their P-ERK status.
These results suggest that the expression of P-ERK is not the
consequence of overexpression of ERK1/2 but rather the result of
hyperactivation of ERK1/2 in the specimens.
Trying to understand whether there is any relationship between
the presence of activated ERK1/2 and the EGF-dependent growth
regulatory pathway in NSCLC, staining of the same samples for
EGFR was carried out. In some systems, activated ERK1/2
correlates well with proliferation. Thus, immunohistochemical
staining for Ki-67 (as a surrogate marker of cell proliferation) was
also performed in this series of tumours. Neither EGFR nor Ki-67
expression correlates in the specimens analysed with activated
ERK1/2 (cytoplasmic or nuclear) as detected by immunohisto-
chemistry (Table 2).
Univariate analysis of clinicopathological factors relevant to
patient survival showed that the following factors studied were
statistically significant for the survival of patients: stage
(P¼ 0.001), T (P¼ 0.001), N (P¼ 0.001) and a positive cytoplasmic
P-ERK staining (P¼ 0.03). Interestingly, the presence of nuclear P-
ERK staining was not statistically significant (P¼ 0.509). Figure 2
shows a Kaplan–Meier plot of patients whose tumours had
positive cytoplasmic staining (15% or more cells with immunos-
tained cytoplasm) and those whose tumours had negative P-ERK
staining (less than 15% of cells with immunostained cytoplasm).
This plot shows that the median survival of patients with positive
P-ERK staining is 57 months (95% confidence interval 11–102
months), whereas for patients with negative staining the median
survival has not been reached, and this difference is statistically
significant with P¼ 0.02. The estimated 5-year survival rate was
43% for patients with positive P-ERK staining vs 77% for patients
whose tumours had negative staining for P-ERK. However,
survival analysis of the NSCLC patients analysed in this study
did not show any significant differences according to the
expression of either EGFR (P¼ 0.18) or Ki-67 (P¼ 0.13).
In order to determine whether P-ERK staining is an independent
prognostic factor in NSCLC, as it is strongly associated with
advanced stages and metastatic tumours, we performed a multi-
variate analysis by adjusting phospho-ERK1/2 activation to clinical
stage (a parameter that depends on T and N), which influences
patient survival. The test showed that patients with negative P-ERK
did not live significantly longer than patients with positive P-ERK
(P¼ 0.69).
DISCUSSION
Although an increased amount of information has been gathered
on the role of the activation of ERK1/2 in a variety of cell lines,
very little is known about its potential role in human cancer. A few
previous reports tried to address this issue by studying the degree
of activation of ERK1/2 in different human tumours. Oka et al
(1995) showed that there was a constitutive activation of ERK1/2 in
48% of renal cancer samples (12 out of 25 patients) when
compared to normal kidney tissue, suggesting that this signalling
pathway could play a role in renal cancer. It was also reported that
activated ERK1/2 was present in 58% of hepatocellular carcinomas
studied, and that this activation was higher than in adjacent
noncancerous lesions (Ito et al, 1998). Another report found no
ERK1/2 activation in normal prostatic tissues and an increased
expression of activated ERK1/2 in prostatic carcinoma tissues in
advanced stages and in recurrent cases (Gioeli et al, 1999). There
was also evidence of activated ERK1/2 in patients with glioma
(Mandell et al, 1998), breast cancer (Sivaraman et al, 1997;
Adeyinka et al, 2002), head and neck cancer (Albanell et al, 2001)
and melanoma (Cohen et al, 2002). In our study, we show for the
first time that normal matching lung tissue in the tumour
specimens analysed, as previously reported for other tumour
types, does not show activated ERK1/2, while activation of ERK1/2
is frequently found in NSCLC. Little evidence existed regarding the
expression of activated ERK1/2 in lung cancer and, specially, in
NSCLC. A previous report showed increased levels of activated
ERK1/2 in a very reduced number of lung cancer tissues when
compared to matching normal lung (Hoshino et al, 1999).
Recently, Blackhall et al (2003) described that ERK1/2 is activated
in SCLC, and Mukohara et al (2003) have studied some elements of
the EGFR signalling pathway in a much smaller number of NSCLC
patients. We have also found that a high percentage of NSCLC
patients (38 out of 111) present ERK1/2 activation. In this regard,
we have seen that a high percentage of positive NSCLC specimens
(50%) presented ERK1/2 activation at the periphery of the tumour.
This pattern of staining had been described by Albanell et al (2001)
in head and neck cancers and also by Mukohara et al (2003) in
NSCLC. Therefore, it seems that activated ERK1/2 is a landmark of
a subset of NSCLC.
In the present work, we used phosphospecific antibodies to
identify activated ERK1/2. The antibody used in this study is the
same antibody used in most of the immunohistochemistry studies
performed to date (Sivaraman et al, 1997; Mandell et al, 1998;
Albanell et al, 2001; Adeyinka et al, 2002; Cohen et al, 2002).
Besides, this antibody was validated in our lab specifically for
formaline-fixed tissues (data not shown). There are other methods
to assess the phospho-ERK status in patient specimens, such as
Western blot. This technique has the inconvenience of requiring a
larger amount of tissue, and that the inclusion of adjacent and
stromal tissues along with the tumour in the extracts may mask the
real activation status of ERK1/2.
Table 2 Clinicopathological factors and their relationship to the
expression of the different proteins assessed
P-ERK
nuclear
P-ERK
cytoplasmic Ki-67 EGFR
Age P¼ 0.7 P¼ 0.115 P¼ 0.277 P¼ 0.143
Sex P¼ 0.349 P¼ 1 P¼ 0.058 P¼ 0.146
Histology P¼ 0.812 P¼ 0.65 P¼ 0.04 P¼ 0.28
Grade P¼ 0.271 P¼0.046 P¼ 0.653 P¼ 0.54
Stage P¼ 0.04 P¼0.000 P¼ 0.902 P¼ 0.3
T P¼0.005 P¼0.000 P¼ 0.586 P¼ 0.58
N P¼0.001 P¼0.000 P¼ 0.897 P¼ 0.64
EGFR P¼ 0.289 P¼ 0.63 P¼ 0.096
Ki-67 P¼ 0.211 P¼ 0.424
Bold type values indicate significance at levels o0.05. P, probability value.
Figure 2 Kaplan–Meier survival plot by cytoplasmic P-ERK expression
(15% cutoff). Survival plot of all patients.
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To our knowledge, only a few studies published to date provide
data on the clinical outcome of patients with activated ERK1/2. In
breast cancer patients, phosphorylated ERK1/2 (as determined by
immunohistochemistry) may predict a poor response to hormonal
therapy and, in a subset of patients, a worse survival (Mueller et al,
2000; Gee et al, 2001). In SCLC, and regarding cytoplasmic staining
of phospho-ERK1/2, the activation of this MAPK positively
correlates with survival. In our work, we have seen a strong
correlation of activated ERK1/2 with some clinicopathological
variables. In particular, we have demonstrated that there is a
strong correlation between positive nuclear and cytoplasmic
staining for P-ERK and more aggressive tumours (i.e. advanced
stage tumours (III and IV), tumours with hilar or mediastinal
lymph node metastases, and tumours with higher T stage), and
also between cytoplasmic staining and the grade of differentiation.
With regard to survival, although we have seen in invariable
analysis that P-ERK cytoplasmic expression may predict poor
survival, multivariate analysis did not confirm that cytoplasmic
ERK activation could be used as an independent prognostic factor.
This may be due to the strong association of P-ERK with advanced
stage tumours, metastatic tumours and tumours with higher T
stage. In NSCLC, a recent report on the expression of EGFR and
downstream-activated signalling factors activated by this receptor
(Mukohara et al, 2003) showed that P-ERK is activated in about
one-third of NSCLC, as we report in the present study in a much
larger series. In contrast to our data, they found no correlation of
the activation of this MAPK with clinicopathological variables.
Another difference in our results with respect to those published
by Mukohara et al (2003) is that we have almost the double
number of patients (n¼ 111 vs N¼ 60). This gives more statistical
support and confidence to the results obtained in this study.
Besides, we have used an antibody that is different from the one
used by Mukohara’s group. We have validated the specificity of the
antibody by specific experiments and by its utilisation in other
studies by previous authors (Sivaraman et al, 1997; Mandell et al,
1998; Albanell et al, 2001; Adeyinka et al, 2002; Cohen et al, 2002).
These two differences may explain the divergent results between
our studies in relation to phospho-ERK and its correlation with
clinicopathological variables.
A previous report showed that in head and neck squamous
cancer, activated ERK1/2 correlated with the expression of the
EGFR (Albanell et al, 2001). In our patients we also looked at the
correlation between EGFR and the expression of activated ERK1/2,
but we did not find such a correlation. It is quite likely that
activation of the EGFR, rather than merely its expression, is what is
relevant in terms of activation of ERK. If this is the case, it could
also be of interest to determine the levels of phospho-EGFR in
addition to the levels of activated ERK1/2 in patients with NSCLC
to test whether patients with a positive staining could benefit from
specific inhibitors of EGFR, like Iressa. In fact, both the
phosphorylated EGFR and P-ERK specific antibodies have already
been used to study the pharmacodynamic effects of Iressa in skin
biopsies of patients treated with the drug (Albanell et al, 2002).
Our results may suggest a greater involvement of other growth
factors in the activation of the ERK1/2 signalling pathway and,
therefore, in the progression of NSCLC. As an example, a potential
role of FGF in NSCLC has already been reported (Berger et al,
1999; Guddo et al, 1999).
Our data also suggest the relevance of the intracellular location
of the immunostaining for P-ERK. In SCLC, Blackhall et al (2003)
had reported that cytoplasmic and not nuclear phospho-ERK
staining correlated with patients survival. In our work, we have
shown that only the cytoplasmic staining was associated with a
poorer survival in NSCLC. As ERK1/2 has both nuclear and
cytoplasmic substrates (Widmann et al, 1999), this observation
could indicate an important role of cytoplasmic substrates of
ERK1/2 in advanced and metastatic tumours. Recently, more
cytoplasmic substrates of phospho-ERK1/2 involved in apoptosis
(such as caspase 9) have been described, indicating that ERK1/2
activation directly regulates programmed cell death (Allan et al,
2003). In lung cancer, although there is some indication of the
possible contribution of some of the nuclear substrates of ERK1/2
to the biology and prognosis of NSCLC patients (Levin et al, 1995;
Volm et al, 2002), very little is known about the possible role of
cytoplasmic substrates of ERK1/2 in NSCLC.
Another potential implication of our findings is related to a new
class of therapeutic agents: the MEK1 inhibitors. Although
inhibitors of MEK1, like PD98059 (Alessi et al, 1995; Dudley et al,
1995) and U0126 (Duncia et al, 1998), have been used for quite a
while in laboratory studies, it was not until recently that the first
compound of this new class of drugs, called PD184352 (Sebolt-
Leopold et al, 1999), entered clinical trials. Previous MEK1
inhibitors lacked solubility, which prevented their use in the
clinical setting. Preliminary results of phase I trials with PD184352
have shown encouraging results, and a clinical trial of this agent in
patients with NSCLC has already started (Dy and Adjei, 2002a).
Monitoring the P-ERK status in biopsies of NSCLC patients
entering clinical trials of the newly introduced inhibitors of MEK1
will help to assess whether an activated ERK1/2 pathway is
necessary for a MEK1 inhibitor to be effective, a question that at
present remains unanswered.
In summary, we have shown that the detection of immunor-
eactivity for P-ERK in patients with NSCLC is associated with
advanced and aggressive tumours. Our data also suggest that the
analysis of ERK1/2 activation may be useful to identify a subgroup
of patients with a poorer prognosis. Finally, our results suggest
that the relevance of P-ERK might not be related to the
proliferation rate of NSCLC but rather to other tumour
characteristics such as the resistance to undergo apoptosis. In
this regard, the role of ERK1/2 in cell survival and regulation of
apoptosis is well established in various systems (Xia et al, 1995;
Mackeigan et al, 2000). Besides, in lung cancer, Brognard and
Dennis (2002) have pointed out the importance of ERK1/2
activation in NSCLC cell lines, where it promotes cell survival
and chemotherapeutic resistance. Further studies are warranted to
explore the role of activated ERK1/2 in patients with NSCLC.
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